Jay M. Moyes

This profile gathers the share dealings of Jay M. Moyes across 4 companies, led by Puma Biotechnology, Inc., BioCardia, Inc. and Sera Prognostics, Inc. In total, 29 filings cover trades dated from 12 June 2018 to 23 February 2026.

Both buying and selling appear: 2 purchases worth €12k, against 7 sales worth €660k. The net balance comes to €649k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 17 share grants and 1 option exercise. Since January 2026: 1 purchase and no sales on the market.

The record was last updated on 25 February 2026 with an open-market purchase (€2,459) in Sintx Technologies, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.